You searched for "hybrid"

KCAS-blog-thumb_2024-HybridLCMS Blogs
Read article Hybrid LC-MS/MS – Frequently Asked Questions

Immunoaffinity LC-MS/MS or hybrid LC-MS/MS is an approach that has been gaining a lot of traction in the past several years.  The technique allows the quantitation of low-level analytes (proteins or peptides in many cases) in biological matrices with exquisite selectivity and sensitivity. Many pharmaceutical companies are trying to expand…

KCAS-blog-thumb_2023_02-KCAS-ADCs-with-Hybrid Blogs
Read article Antibody Drug Conjugate Services from KCAS and What Hybrid Technology Contributes

Anyone who has been following KCAS for any amount of time has likely heard us discuss the advantages of Hybrid LC-MS/MS for the bioanalysis of large molecules. As pioneers in the technology for many years, KCAS has become a strong proponent of working with our customers to demonstrate the quality…

HybridLCMS-LargeMolecules November 15 - November 17

For years, Dawn Dufield, PhD and I have been doing our best to get the word out (via as many venues as possible) about KCAS’s unique expertise with hybrid LC-MS/MS. This year’s upcoming EBF meeting in Barcelona is just such an opportunity, and one we are very much looking…

KCAS-blog-thumb_2022_Hybrid-New-Gold-Standard-1 Blogs
Read article Is Hybrid LC-MS/MS becoming the new Gold Standard?

Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays. However, we urge people to be open to a more flexible approach. Using hybrid LC-MS/MS can be an equally useful tool for quantitation of biological therapeutics and…

KCAS-blog-thumb_2024-Panel Webinars
View webinar Register Today for An Informative Panel Discussion Exploring Advanced Biopharmaceutical Quantification Techniques

For researchers and professionals working in the biopharmaceutical industry, an upcoming Bioanalysis Zone Panel Discussion will offer a unique opportunity to stay informed about the latest advancements in quantitative analysis techniques. Research projects can only succeed when selecting the appropriate biopharmaceutical quantification technique. Staying up-to-date on…

PATTERN_BLUE_1320x780 Blogs
Read article Is Hybrid LC-MS/MS Emerging as an Equal Partner to LBA for the Analysis of Biotherapeutics?

There has been an increasing focus on large molecule therapeutics and pharmaceutical companies have increasingly aligned their development pipelines in that direction. This has resulted in more biological therapeutics coming to market.  Last year,…

KCAS-blog-thumb_2022_Webinar-Hybrid-Gold-Standard-1 Webinars
View webinar KCAS Webinar: “Is Hybrid LC-MS/MS becoming the new Gold Standard?”

Originally produced by Xtalks on Friday, April 22, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)  60 min Webinar Description: Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays.

KCAS-blog-thumb_2024-ADCsHybridTech Blogs
Read article Harnessing the Potential of Hybrid Technology in Antibody Drug Conjugate Services

In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…

PATTERN_ORANGE_1320x780_2 Blogs
Read article What is Hybrid LC-MS/MS and How Can It Benefit You?

What is Hybrid LC-MS/MS? Technically Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. Usually it only requires one antibody, whereas a typical LBA technique will require two. Following affinity capture, it is common to include a digestion step to produce surrogate peptides, which are…

KCAS-blog-thumb_2024-01B_JPM-ADCs Blogs
Read article ADCs at the Forefront of J.P. Morgan Annual Conference in 2024

If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the mood…

KCAS-podcast-thumb_TWB-066 Podcasts
Listen to podcast The Weekly Bioanalysis Podcast Eps #66: “Recent Advances in Hybrid LC-MS/MS with Special Guests”

Special guests Dawn Duffield, PhD of KCAS and Barry Jones, PhD of Crinetics join John and Dom in the 66th episode of “The Weekly Bioanalysis” to discuss the ways Hybrid LC-MS/MS has advanced in recent years and how the technology has gone from “new” and somewhat obscure to…

KCAS-blog-thumb_Large-Mol-Challenges-p2 Blogs
Read article Large Molecule Therapeutics Challenges and Solutions (part 2)

To read part one of this 2-part series, click here. With increasing focus on large molecule therapeutics and interest in large molecule biomarkers it’s essential to have LC/MS available as a complimentary technology to ligand…

PATTERN_ORANGE_1320x780_2 Blogs
Read article Putting the Luminex to Work: Which of KCAS’ newest biomarkers is right for you?

Biomarker is a broad term and can mean so many different things depending upon the scientific discipline. For Bioanalytical biomarker analysis – and specifically for CROs equipped with 9 different platforms to measure biomarkers and a cell culture suite with up to 19 color flow cytometry all under one roof…

PATTERN_AMBER_1320x780_3 Blogs
Read article 505(b)(2) Drug Development: A Bioanalytical Lab’s Perspective

The 505(b)(2) drug development path, in contrast to traditional development of a new, never been approved drug (described under 505(b)(1) of the Federal Food, Drug, and Cosmetic Act) or ANDA (described under Section 505(j) of the Act) for a generic drug that is no longer under patent…

KCAS-event_2024-03_KnowledgeForGrowth May 15 - May 16

Knowledge for Growth (KfG) is Europe’s premier life sciences conference, held annually in Antwerp, Belgium. This year’s edition celebrates the industry’s advancements with a hybrid format, catering to both in-person and virtual attendees. The program features captivating talks, scientific sessions on cutting-edge topics like gene editing and personalized medicine, and…

PATTERN_BLUE_1320x780_2 November 15 - November 17

Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…

KCAS-blog-thumb_2023-09A_LBAs-Plethora Blogs
Read article Ligand Binding Assays: a Plethora of Technologies to Address Your Projects’ Requirements

Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the…

PATTERN_BLUE_1320x780_2 Blogs
Read article Q and A: Immunoaffinity and Hybrid LC-MS/MS

Biomarker are key drivers in the drug development process.  Frequently, developing a panel of biomarkers to test a particular mechanism or hypothesis is critical to the success of a drug.  At KCAS, we develop assays for custom panels or individual biomarkers based on client needs and can also assist with…

KCAS-blog-thumb_2022_LBA-and-LCMSMS Blogs
Read article Combining the Benefits of LBA and LC-MS/MS for Pharmacodynamics at KCAS

Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies how…

PATTERN_BLUE_1320x780 Blogs
Read article KCAS is a Solution-Based Company, Focused on the Delivery of high-Quality Scientific and Defendable Data

KCAS is a solution-based company. We are focused on the delivery of high quality scientific and defendable data, able to meet or exceed client’s timelines and expectations. One of the main reasons we are able to deliver on even the most challenging projects and programs, is the technical breadth and…

PATTERN_ORANGE_1320x780 Webinars
View webinar KCAS Bio Webinar “Navigating the Complex Landscape of Lipid Panels & Small Molecule Biomarkers in Drug Discovery”

Produced by AAPS Organized by Sciex Recorded on December 6, 2023 eChalkTalk available here.  Webinar Description: In this webinar, scientists from KCAS Bio, along with specialists from SCIEX Biopharma & Pharma Solutions discuss • Developing robust assays for PD biomarkers and their challenges…

KCAS-blog-thumb_2023-07B_PK-ADCs Blogs
Read article Recent FDA Guidance for Pharmacokinetics and Antibody Drug Conjugates, and What They Mean for Your Projects at KCAS

With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…

KCAS-blog-thumb_2022_Molecular-CGT Blogs
Read article Molecular Cell & Gene Therapy Solutions from KCAS

With the extensive advances in technologies like CRISPR and CAR-T, cell and gene therapy has grown to become a viable way for treating Cancer as well as other diseases. Our team has over 100+ years of collective expertise in molecular services using qPCR and ddPCR for support of…

PATTERN_AMBER_1320x780_2 Blogs
Read article The Age of Cell & Gene Therapies is Upon Us. So What Does That Mean?

Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells).  As of…